FEMALE HEALTH CO
SC 13D/A, 1999-05-10
FABRICATED RUBBER PRODUCTS, NEC
Previous: PETSMART INC, 8-K/A, 1999-05-10
Next: EUROPEAN WARRANT FUND INC, DEF 14A, 1999-05-10



<PAGE>
 
                                 UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                 SCHEDULE 13D

                   UNDER THE SECURITIES EXCHANGE ACT OF 1934
                              (AMENDMENT NO. 2)*

                           The Female Health Company
                  ------------------------------------------
                                (Name of Issuer)

                       Common Stock, $0.01 par value
                  ------------------------------------------
                         (Title of Class of Securities)

                                  314462 10 2
                  ------------------------------------------
                                (CUSIP Number)

                              Stephen M. Dearholt
        741 N. Milwaukee Street, Suite 500, Milwaukee, Wisconsin 53202
        --------------------------------------------------------------
           (Name, Address and Telephone Number of Person Authorized
                    to Receive Notices and Communications)

                                March 25, 1999
     --------------------------------------------------------------------
            (Date of Event which Requires Filing of this Statement)



If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box [_].

NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits.  See Rule 13d-7(b) for other
parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
 
                                 SCHEDULE 13D
- -----------------------                                  ---------------------
  CUSIP NO. 314462 10 2                                    PAGE   OF    PAGES
- -----------------------                                  ---------------------
 
- ------------------------------------------------------------------------------
      NAME OF REPORTING PERSON
 1    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
                          
      Stephen M. Dearholt                
- ------------------------------------------------------------------------------
      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 2                                                              (a) [_]
                                                                (b) [_]
- ------------------------------------------------------------------------------
      SEC USE ONLY
 3
        
- ------------------------------------------------------------------------------
      SOURCE OF FUNDS*
 4     
      PF
- ------------------------------------------------------------------------------
      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT 
      TO ITEMS 2(d) or 2(e) [_]
 5    
- ------------------------------------------------------------------------------
      CITIZENSHIP OR PLACE OF ORGANIZATION
 6    
      Wisconsin, USA
- ------------------------------------------------------------------------------
                          SOLE VOTING POWER
                     7     
     NUMBER OF            
                          1,261,555
      SHARES       -----------------------------------------------------------
                          SHARED VOTING POWER
   BENEFICIALLY      8    
                          226,229
     OWNED BY                    
                   -----------------------------------------------------------
       EACH               SOLE DISPOSITIVE POWER
                     9     
    REPORTING             1,261,555
                         
      PERSON       -----------------------------------------------------------
                          SHARED DISPOSITIVE POWER
       WITH          10   
                          226,229
- ------------------------------------------------------------------------------
      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11    
      
      1,487,784
- ------------------------------------------------------------------------------
      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12                  
      [_]
- ------------------------------------------------------------------------------
      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13    
      12.4%       
- ------------------------------------------------------------------------------
      TYPE OF REPORTING PERSON*
14
      IN
- ------------------------------------------------------------------------------
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!
         INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
     (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.

Mr. Dearholt has disclosed his ownership of The Female Health Company's (the
"Company") Common Stock ("Issuer Common Stock") to the Company; in turn, that
ownership has been reported in certain of the Company's proxy statements. This
filing is being made to address his independent filing obligations under Section
13(d) of the Securities Exchange Act of 1934, as amended.

                                       2
<PAGE>
 
Item 1.   Security and Issuer
- -------   -------------------

     This statement relates to the Common Stock, par value $0.01 per share (the
"Issuer Common Stock"), of The Female Health Company, a Wisconsin corporation
(the "Company").  The principal executive offices of the Company are located at
875 North Michigan Avenue, Suite 3660, Chicago, Illinois 60611.

Item 2.   Identity and Background
- -------   -----------------------

(a)-(c) and (f)

     This Schedule 13D is filed on behalf of Stephen M. Dearholt, a Wisconsin
resident individual and a United States citizen ("Mr. Dearholt").  Mr. Dearholt
is co-founder of and a partner in Response Marketing, a privately held life
insurance marketing organization.  Mr. Dearholt has been a director of the
Company since 1996.  The principal address of Mr. Dearholt is 741 N. Milwaukee
St., Suite 500, Milwaukee, Wisconsin 53202.

(d) and (e)

     During the last five years, Mr. Dearholt has not (i) been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors) or
(ii) been a party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.

     Information called for by Item 2 for persons with whom Mr. Dearholt shares
voting power for shares of Issuer Common Stock will be provided by amendment, if
applicable.

Item 3.   Source and Amount of Funds or Other Consideration
- -------   -------------------------------------------------

     From August 28, 1990 through the present, Mr. Dearholt has purchased an
aggregate of 260,075 (12,000 shares of which were sold in October, 1998) shares
of the Issuer Common Stock in open market transactions.  Such shares were
purchased for cash, obtained from personal investment funds.

     On November 21, 1995, an affiliate of Mr. Dearholt loaned $1,000,000 to the
Company.  Mr. Dearholt guaranteed the Company's repayment of the loan. The
Company granted Mr. Dearholt a warrant to purchase 10,000 shares of Issuer
Common Stock in connection therewith.  The warrant contains certain anti-
dilution rights that entitle Mr. Dearholt to purchase a number of shares of
Issuer Common Stock equal to 0.14% of the issued and outstanding shares of
Issuer Common Stock (including as outstanding shares any shares issuable upon
exercise or conversion of any warrants, rights, options or securities) on the
date the warrant is exercised.

     On March 25, 1996, Mr. Dearholt loaned the Company $1,000,000 to fund the
Company's working capital needs and to fund operating losses.  The loan by 

                                       3
<PAGE>
 
Mr. Dearholt was made from personal investment funds. Through the loan of such
funds by Mr. Dearholt and the extension of such loan, the Company has issued Mr.
Dearholt warrants to purchase an aggregate of 800,000 shares of Issuer Common
Stock.

     On various dates since July 31, 1990, Mr. Dearholt has purchased 6,200
shares of Issuer Common Stock for the benefit of Mr. Dearholt's self-directed
IRA.  These shares of Issuer Common Stock for Mr. Dearholt were purchased with
cash deferred from Mr. Dearholt's income.

     On various dates since August 13, 1990, Mr. Dearholt has purchased 69,500
shares of Issuer Common Stock for the benefit of the Dearholt, Inc. Profit
Sharing Plan.  These shares of Issuer Common Stock were purchased with cash
contributed by Dearholt, Inc. to the Profit Sharing Plan for the benefit of the
employees of Dearholt, Inc.

     On various dates since August 1, 1991, Mr. Dearholt has purchased an
aggregate of 18,100 shares of Issuer Common Stock for the benefit of his minor
child.  These shares of Issuer Common Stock were purchased with cash obtained
from personal investment funds.

     On various dates since February 20, 1994, the Mary C. Dearholt Trust, of
which Mr. Dearholt is co-trustee, has purchased an aggregate of 141,240 shares
of Issuer Common Stock.  These shares of Issuer Common Stock were purchased with
cash from such trust's investment funds.

     On various dates since October 27, 1992, North Central Trust has purchased
an aggregate of 9,680 shares of Issuer Common Stock for the Response Marketing
Money Purchase Plan.  North Central Trust has the sole power to vote and dispose
of the shares held in this plan.  Mr. Dearholt is a co-founder of and a partner
in Response Marketing.  The shares of Issuer Common Stock were purchased with
cash contributed by Response Marketing for the benefit of its employees.

     On May 31, 1996, the Phoenix Healthcare Group Limited Partnership dissolved
and distributed 18,100 shares of Issuer Common Stock to the James W. Dearholt
Trust of which Mr. Dearholt is a co-trustee with a sibling.  The James W.
Dearholt Trust was a limited partner in the Phoenix Healthcare Group Limited
Partnership.  The interest in the limited partnership was purchased with cash
from such trust's investment funds.

     On July 27, 1997, the Mary C. Dearholt Trust purchased 60,000 shares of the
Company's Class A Convertible Preferred Stock - Series 1 at a price of $2.50 per
share, which represented the per share price offered to all subscribers in the
private placement offering of these shares.  The shares of the Company's
Preferred Stock were purchased with cash obtained from such trust's investment
funds.

     On October 5, 1998, the Company issued 6,889 shares of Issuer Common Stock
to the Mary C. Dearholt Trust in lieu of paying interest in cash on the 60,000
shares of preferred stock owned by the Mary C. Dearholt Trust.

                                       4
<PAGE>
 
     On February 12, 1999, Mr. Dearholt loaned the Company $250,000 to fund the
Company's working capital needs.  The loan by Mr. Dearholt was made from
personal investment funds.  The Company granted Mr. Dearholt a warrant to
purchase 50,000 shares of Issuer Common Stock in connection therewith.

Item 4.   Purpose of Transaction
- -------   ----------------------

     Mr. Dearholt has been a long time investor in the Company, with his
investment in the Company having been acquired, and continuing to be acquired,
for investment purposes.

     On April 22, 1996, Mr. Dearholt was elected by the Company to its Board of
Directors.  Mr. Dearholt did not solicit a seat on the Company's board but
accepted when offered a board position.

     Other than the foregoing, Mr. Dearholt has no plans or proposals which
would result in the acquisition or disposition of Issuer Common Stock or for any
other action that should be enumerated in Item 4 of Schedule 13D.

Item 5.   Interest in Securities of the Issuer
- -------   ------------------------------------

                                 Amount of Beneficial Ownership
Name of Beneficial Owner            Shares          Percent
Stephen M. Dearholt (1)(2)        1,487,784          12.4%

     (1) Includes options to purchase 50,000 shares (which are currently
     exercisable) granted pursuant to the terms of the Company's Outside
     Director Stock Option Plan.

     (2) Includes 248,075 shares owned directly by Mr. Dearholt and warrants to
     purchase 860,000 shares which are currently exercisable.  Also includes the
     following shares which Mr. Dearholt may be deemed to beneficially own:
     69,500 shares held by the Dearholt, Inc. Profit Sharing Plan; 9,680 shares
     held by the Response Marketing Money Purchase Plan; 6,200 shares held in a
     self-directed IRA; 148,129 shares held by the Mary C. Dearholt Trust of
     which Mr. Dearholt, a sibling and his mother are trustees; 18,100 shares
     held by Mr. Dearholt's minor child; 18,100 shares held by the James W.
     Dearholt Trust of which Mr. Dearholt is a co-trustee with a sibling, and
     60,000 shares of preferred stock held by the Mary C. Dearholt Trust that
     are convertible share-for-share into Issuer Common Stock.  Mr. Dearholt
     shares the power to vote and dispose of 226,229 shares of Issuer Common
     Stock (including 60,000 shares of Preferred Stock convertible into Issuer
     Common Stock) held by the Mary C. Dearholt Trust and the James W. Dearholt
     Trust.  Mr. Dearholt has sole power to vote and dispose of the remaining
     shares of Issuer Common Stock reported herein, except that North Central
     Trust has the sole power to vote and dispose of the 9,680 shares of Issuer
     Common Stock held by the Response Marketing Money Purchase Plan.

                                       5
<PAGE>
 
     On March 25, 1996, the Company borrowed $1,000,000 from Mr. Dearholt under
a one year note payable in full March 25, 1997 with interest at 12% payable
monthly.  As part of this transaction, the Company issued a warrant to Mr.
Dearholt which entitles him to purchase 200,000 shares of Issuer Common Stock at
$3.10 per share, which represented the average trading price of Issuer Common
Stock for the five trading days prior to the originally scheduled closing date
for the transaction.  The warrant expires upon the earlier of its exercise or
2002.  The note was repaid by issuance of a new promissory note due March 25,
1998, a replacement note due March 25, 1999 and a subsequent replacement note
due on March 25, 2000.  The one outstanding promissory note is now payable in
full on March 25, 2000 and bears interest at 12% per annum payable monthly.  The
note proceeds were initially used by the Company to provide working capital
needed to fund the initial stages of the Company's U.S. marketing campaign and
to fund operating losses.  The borrowing transactions were effected in the form
of a promissory note from the Company to Mr. Dearholt and related Note Purchase
and Warrant Agreements and Stock Issuance Agreements.   The Company has issued
an additional warrant to purchase 200,000 shares of Issuer Common Stock each
time a new promissory note was issued to Mr. Dearholt at exercise prices of
$1.848, $2.25 and $1.16 per share, respectively, and have expiration dates of
March 25, 2004, 2006 and 2008, respectively. Under the only Stock Issuance
Agreement currently in effect with respect to this financing and extensions
thereof, if the Company fails to repay the $1,000,000 under the outstanding note
when due, the Company must issue 200,000 shares of Issuer Common Stock to Mr.
Dearholt. The Company also granted Mr. Dearholt certain securities registration
rights for the Issuer Common Stock he receives from the Company under the
warrants or the Stock Issuance Agreement. When Mr. Dearholt agreed to extend the
formerly outstanding promissory note for an additional one year term to be due
and payable on March 25, 2000, the Company extended the term of certain warrants
held by Mr. Dearholt which were to expire on March 25, 2001 to March 25, 2002.

     On February 12, 1999, the Company borrowed $250,000 from Mr. Dearholt under
a one year note payable in full February 12, 2000 with interest at 12% payable
monthly.  As part of this transaction, the Company issued a warrant to Mr.
Dearholt which entitles him to purchase 50,000 shares of Issuer Common Stock at
$1.248 per share (the average of the last bid and ask prices as quoted through
the NASDAQ Work Station II on February 12, 1999, less a discount of 20% of said
average).  The borrowing transaction was effected in the form of a promissory
note from the Company to Mr. Dearholt and related Note Purchase and Warrant
Agreement and Stock Issuance Agreement.  The warrant expires upon the earlier of
its exercise or February 12, 2007.  Under the Stock Issuance Agreement, if the
Company fails to repay the $250,000 under the note when due, the Company must
issue 50,000 shares of Issuer Common Stock to Mr. Dearholt.  The Company also
granted Mr. Dearholt certain securities registration rights for the Issuer
Common Stock he receives from the Company under the warrant or the Stock
Issuance Agreement.

     Mr. Dearholt purchased, in the market, an aggregate of 10,000 shares of
Issuer Common Stock on April 19, 1999, at $1.375 per share.  All shares were
purchased solely for investment purposes.

                                       6
<PAGE>
 
Item 6.   Contracts, Arrangements, Understandings or Relationships with Respect
- -------   ---------------------------------------------------------------------
          to Securities of the Issuer
          ---------------------------

          See the relationships and arrangements discussed in Items 3 and 5. If
applicable, future information will be filed by amendment.
 
Item 7.   Material to be Filed as Exhibits
- -------   --------------------------------

Exhibit No.
- -----------

1         Warrant to purchase shares of Issuer Common Stock issued to Stephen M.
          Dearholt dated as of November 21, 1995.*

2         Warrant to purchase up to 200,000 shares of Issuer Common Stock issued
          to Stephen M. Dearholt dated as of March 25, 1996.*

3         Warrant to purchase up to 200,000 shares of Issuer Common Stock issued
          to Stephen M. Dearholt dated as of March 25, 1997.*

4         Warrant to purchase up to 200,000 shares of Issuer Common Stock issued
          to Stephen M. Dearholt dated as of March 25, 1998.*

5         Note Purchase and Warrant Agreement between the Company and Stephen M.
          Dearholt dated March 25, 1998.*

6         Stock Issuance Agreement between the Company and Stephen M. Dearholt
          dated as of March 25, 1998.*

7.        Warrant to purchase up to 50,000 shares of Issuer Common Stock issued
          to Stephen M. Dearholt dated as of February 12, 1999.**

8.        Note Purchase and Warrant Agreement between the Company and Stephen M.
          Dearholt dated February 12, 1999.**

9.        Stock Issuance Agreement between the Company and Stephen M. Dearholt
          dated as of February 12, 1999.**

10.       Warrant to purchase up to 200,000 shares of Issuer Common Stock issued
          to Stephen M. Dearholt dated as of March 25, 1999.**

11.       Note Purchase and Warrant Agreement between the Company and Stephen M.
          Dearholt dated March 25, 1999.**

12.       Stock Issuance Agreement between the Company and Stephen M. Dearholt
          dated as of March 25, 1999.**

 *Previously filed with Amendment No. 1 to Schedule 13D on January 14, 1999.
**To be filed by amendment.

                                       7
<PAGE>
 
                                   SIGNATURE
                                   ---------

          After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
 

                              /s/ Stephen M. Dearholt
                              ---------------------------------  
                              Stephen M. Dearholt
 

                              Dated:  May 7, 1999

                                       8


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission